Yanli Wang

Dr. Yanli Wang

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 November 2023 in Advanced Science
Verified
Journal Article
Open access
PMPrasenjit Mondal
Prasenjit Mondal
PBPing Bai
Ping Bai
AGAshley Gomm
Ashley Gomm
GBGrisilda Bakiasi
Grisilda Bakiasi
CLChih‐Chung Jerry Lin
Chih‐Chung Jerry Lin
Can ZhangCan Zhang
Can Zhang
Histone deacetylase 6 (HDAC6) is one of the key histone deacetylases (HDACs) that regulates various cellular functions including clearance of misfolded protein and immunological responses. Considerable evidence suggests that HDAC6 is closely related to amyloid and tau pathology, the two primary hallmarks of Alzheimer's disease (AD). It is still unclear whether HDAC6 expression changes with amyloid deposition in AD during disease progression or HDAC6 may be regulating amyloid phagocytosis or neuroinflammation or other neuropathological changes in AD. In this work, the pathological accumulation of HDAC6 in AD brains over age as well as the relationship of its regulatory activity ‐ with amyloid pathogenesis and pathophysiological alterations is aimed to be enlightened using the newly developed HDAC6 inhibitor (HDAC6i) PB118 in microglia BV2 cell and 3D‐AD human neural culture model. Results suggest that the structure‐based rational design led to biologically compelling HDAC6i PB118 with multiple mechanisms that clear Aβ deposits by upregulating phagocytosis, improve tubulin/microtubule network by enhancing acetyl α‐tubulin levels, regulate different cytokines and chemokines responsible for inflammation, and significantly reduce phospho‐tau (p‐tau) levels associated with AD. These findings indicate that HDAC6 plays key roles in the pathophysiology of AD and potentially serves as a suitable pharmacological target through chemical biology‐based drug discovery in AD.

4 December 2023 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
JZJing Zhang
Jing Zhang
CWCarly Wickizer
Carly Wickizer
WDWeihua Ding
Weihua Ding
RVRichard Van
Richard Van
LYLiuyue Yang
Liuyue Yang
CRChongzhao Ran
Chongzhao Ran
Optical three-dimensional (3D) molecular imaging is highly desirable for providing precise distribution of the target-of-interest in disease models. However, such 3D imaging is still far from wide applications in biomedical research; 3D brain optical molecular imaging, in particular, has rarely been reported. In this report, we designed chemiluminescence probes with high quantum yields, relatively long emission wavelengths, and high signal-to-noise ratios to fulfill the requirements for 3D brain imaging in vivo. With assistance from density-function theory (DFT) computation, we designed ADLumin-Xs by locking up the rotation of the double bond via fusing the furan ring to the phenyl ring. Our results showed that ADLumin-5 had a high quantum yield of chemiluminescence and could bind to amyloid beta (Aβ). Remarkably, ADLumin-5’s radiance intensity in brain areas could reach 4 × 10 7 photon/s/cm 2 /sr, which is probably 100-fold higher than most chemiluminescence probes for in vivo imaging. Because of its strong emission, we demonstrated that ADLumin-5 could be used for in vivo 3D brain imaging in transgenic mouse models of Alzheimer’s disease.

1 December 2020 in Annals of Translational Medicine
Verified
Journal Article
Open access
PDF file
RYRong Yang
Rong Yang
YZYuwei Zhou
Yuwei Zhou
YWYanli Wang
Yanli Wang
CDChengli Du
Chengli Du
YWYihe Wu
Yihe Wu
Background: Cancer is the second leading cause of death in the United States (US). The goal of this study was to characterize the trends in cancer incidence and mortality in the US from 1975 to 2016. Methods: In this study, we analyzed 4,711,958 cancer cases and 21,489,462 cancer death cases from the Surveillance, Epidemiology and End Results (SEER) database. Cancer incidence and mortality were assessed according to sex, race, and age group. Cancer survival rates between 2010 and 2016 were also examined. Results: The continuous decline in the overall cancer mortality rate from the early 1990s has resulted in overall decreases of 33.6% and 23.6% in the cancer mortality rates of males and females, respectively. In males, the top three leading cancers and causes of cancer death from 1975 to 2016 were prostate, lung and bronchial, and colon and rectal cancers, while in females, the top three leading cancers and causes of cancer death from 1979 to 2016 were breast, lung and bronchial, and colon and rectal cancers. The 5-year relative survival rates of males and females for all cancers combined, diagnosed from 2010–2016, were 68.5% and 70.1%, respectively. The overall cancer incidence and mortality were higher in males than females from 1975–2016. Also, black people had higher mortality and shorter survival rates for all cancers combined compared with white people (in both sexes). Conclusions: This study presents a comprehensive overview of cancer incidence and mortality in the US over the past 42 years. Such information can provide a scientific basis for cancer prevention and control.

12 April 2024 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
PBPing Bai
Ping Bai
FBFrederick A. Bagdasarian
Frederick A. Bagdasarian
YXYulong Xu
Yulong Xu
YWYanli Wang
Yanli Wang
YWYongle Wang
Yongle Wang
CWChangning Wang
Changning Wang

1 February 2016 in Tissue and Cell
Verified
Journal Article
Closed access
JLJunrong Li
Junrong Li
TSTing Shen
Ting Shen
YWYanli Wang
Yanli Wang
QWQuanwei Wei
Quanwei Wei
FSFang-Xiong Shi
Fang-Xiong Shi

11 December 2024 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
YWYongle Wang
Yongle Wang
YWYanli Wang
Yanli Wang
YXYulong Xu
Yulong Xu
HCHua Cheng
Hua Cheng
TDTEWODROS MULUGETA DAGNEW
TEWODROS MULUGETA DAGNEW
CWChangning Wang
Changning Wang
Background: Bromodomain and extra-terminal (BET) proteins are critical regulators of gene transcription, as they recognize acetylated lysine residues. The BD1 bromodomain of BRD4, a member of the BET family, has emerged as a promising therapeutic target for various diseases. This study aimed to develop and evaluate a novel C-11 labeled PET radiotracer, [11C]YL10, for imaging the BD1 bromodomain of BRD4 in vivo. Methods: [11C]YL10 was synthesized and evaluated for its ability to bind to the BD1 bromodomain selectively. PET imaging studies were conducted in mice to assess brain penetration, pharmacokinetics, and selectivity. In vitro autoradiography and blocking experiments were performed to confirm the tracer’s specificity for the BD1 domain. Results: [11C]YL10 demonstrated good brain penetration, high selectivity for the BD1 bromodomain, and favorable pharmacokinetics in initial PET imaging studies. In vitro autoradiography and blocking experiments confirmed the specific binding of [11C]YL10 to the BD1 domain of BRD4, further validating its potential as a targeted radiotracer. Conclusions: The development of [11C]YL10 provides a new tool for studying BRD4 bromodomains using PET imaging technology. This radiotracer offers potential advancement in the diagnosis and research of neurodegenerative diseases and related disorders involving BRD4 dysregulation.